OppenheimerFunds’s Alnylam Pharmaceuticals ALNY Stock Holding History

OppenheimerFunds’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-73,840	Closed	-$5.93M	–	1740
2015 Q3	$5.93M	Buy	73,840 +6,520	+10%	+$724K	0.01%	801
2015 Q2	$8.07M	Buy	67,320 +5,150	+8%	+$615K	0.01%	786
2015 Q1	$6.49M	Buy	62,170 +3,160	+5%	+$320K	0.01%	816
2014 Q4	$5.72M	Buy	+59,010	New	+$5.47M	0.01%	820
2014 Q3	–	Sell	-146,300	Closed	-$9.24M	–	911
2014 Q2	$9.24M	Buy	146,300 +170	+0.1%	+$10.1K	0.01%	768
2014 Q1	$9.81M	Sell	146,130 -36,150	-20%	-$2.8M	0.01%	757
2013 Q4	$11.7M	Buy	+182,280	New	+$10.9M	0.01%	702

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

OppenheimerFunds's ALNY Position: Q4 2015 in Review

OppenheimerFunds sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2015, closing a stake of 73,840 shares — an estimated $5.93M sold.

OppenheimerFunds first reported a position in ALNY in Q4 2013 and held it in 7 quarters. The position peaked at $11.7M in Q4 2013. 261 funds tracked by Wall St. Rank hold ALNY as of Q4 2015.

OppenheimerFunds reported no remaining Alnylam Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
OppenheimerFunds sold 73,840 Alnylam Pharmaceuticals shares in Q4 2015, an estimated $5.93M.
OppenheimerFunds first reported a position in Alnylam Pharmaceuticals in Q4 2013 and held it in 7 quarters.
OppenheimerFunds's Alnylam Pharmaceuticals position peaked at $11.7M in Q4 2013.
261 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2015.

Based on OppenheimerFunds's 13F filing for Q4 2015, filed 5 Feb 2016.